Royalty Pharma plc Proceeds from Long-term Lines of Credit
Royalty Pharma plc (RPRX) reported Proceeds from Long-term Lines of Credit of $1.27 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-02-11
- Royalty Pharma plc proceeds from long-term lines of credit for the quarter ending 2025-12-31 was $0.00.
- Royalty Pharma plc proceeds from long-term lines of credit for the quarter ending 2024-12-31 was $0.00.
- Royalty Pharma plc proceeds from long-term lines of credit for fiscal 2025 was $1.27B.
- Royalty Pharma plc proceeds from long-term lines of credit for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Royalty Pharma plc proceeds from long-term lines of credit for fiscal 2023 was $350.00M.
- Royalty Pharma plc proceeds from long-term lines of credit for fiscal 2022 was $0.00.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.27B 10-K · filed 2026-02-11 | |
| 2025-09-30 | $1.27B 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $350.00M 10-K · filed 2026-02-11 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-12 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |